Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Cash & Equivalents (2021 - 2026)

Centessa Pharmaceuticals has reported Cash & Equivalents over the past 5 years, most recently at $61.3 million for Q4 2025.

  • Quarterly Cash & Equivalents fell 84.0% to $61.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.3 million through Dec 2025, down 84.0% year-over-year, with the annual reading at $61.3 million for FY2025, 84.0% down from the prior year.
  • Cash & Equivalents was $61.3 million for Q4 2025 at Centessa Pharmaceuticals, up from $50.8 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $595.1 million in Q4 2021 and troughed at $44.2 million in Q2 2025.
  • The 5-year median for Cash & Equivalents is $171.5 million (2023), against an average of $261.9 million.
  • Year-over-year, Cash & Equivalents soared 199.32% in 2024 and then crashed 87.14% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $595.1 million in 2021, then plummeted by 33.85% to $393.6 million in 2022, then crashed by 67.48% to $128.0 million in 2023, then soared by 199.32% to $383.2 million in 2024, then crashed by 84.0% to $61.3 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Cash & Equivalents are $61.3 million (Q4 2025), $50.8 million (Q3 2025), and $44.2 million (Q2 2025).